natgillin/translations-raw huggingface dataset:
The powder vial contains white powder and the pre-filled syringe contains a clear colourless solution. 
Viala s praškom vsebuje bel prašek, napolnjena injekcijska brizga pa bistro in brezbarvno raztopino.
• in patients with acquired haemophilia 
• pri bolnikih s pridobljeno hemofilijo,
- Store powder and solvent below 25°C. 
- Prašek in topilo shranjujte pri temperaturi do 25 °C.
• Pull the plunger to draw in a volume of air that is equal to the amount of solvent in the solvent vial (ml equals cc on the syringe). 
• Potegnite bat nazaj, tako da potegnete v brizgo natanko toliko zraka, kolikor je topila v viali s topilom (mililitri ustrezajo oznaki cc na brizgi).
Please refer to outer packaging for present pack size. 
Za velikost tega pakiranja glejte zunanjo ovojnino.
When you prepare and inject medication directly into the vein, it is important to use a clean and germ free (aseptic) technique. 
Pomembno je, da med pripravo in injiciranjem zdravila v veno uporabljate čist postopek brez klic (aseptičen postopek).
Dose limiting toxicities of NovoSeven have not been investigated in clinical trials. 
V kliničnih preskušanjih niso raziskali toksičnih učinkov, ki omejujejo odmerek zdravila NovoSeven.
Remove the plastic caps from the two vials. 
Odstranite plastična pokrovčka z obeh vial.
NovoSeven is a blood coagulation factor. 
Kaj je zdravilo NovoSeven in za kaj ga uporabljamo Zdravilo NovoSeven je krvni koagulacijski faktor.
You should talk to your doctor before using NovoSeven if you also use Factor VIII or IX products. 
Če uporabljate zdravila, ki vsebujejo faktor VIII ali IX, se posvetujte s svojim zdravnikom, preden uporabite zdravilo NovoSeven.
As the total number of treatment episodes in clinical trials is below 10,000, the lowest possible frequency of adverse drug reactions that can be assigned is rare (> 1/10,000 to < 1/1,000). 
10.000 epizod zdravljenja, je "redko" (≥ 1/10.000 do < 1/1.000) najmanjša pogostnost, ki jo lahko določimo.
- Venous thromboembolic events (deep vein thrombosis, thrombosis at i.v. 
- venski trombembolični dogodki (globoka venska tromboza, tromboza na mestu intravenske aplikacije,
In addition, the development of antibodies against NovoSeven and FVII has been associated with overdose in one patient with factor VII deficiency. 
Poleg tega je bilo preveliko odmerjanje pri enem bolniku s pomanjkanjem faktorja VII povezano s pojavom protiteles proti zdravilu NovoSeven in FVII.
A higher risk of arterial thromboembolic adverse events (see table: Vascular disorders) (5.6% in patients treated with NovoSeven versus 3.0% in placebo-treated patients) has been shown in a meta-analysis of pooled data from placebo-controlled trials conducted outside current approved indications in various clinical settings, each of these having distinct patient characteristics and hence different underlying risk profiles. 
Opravljena je bila metaanaliza kumulativnih podatkov s placebom kontroliranih preskušanj, opravljenih zunaj trenutno odobrenih indikacij v različnih kliničnih okoliščinah, od katerih ima vsaka posebne značilnosti bolnikov in s tem različne osnovne profile tveganja.
In post-marketing experience, there have been no reports of inhibitory antibodies against NovoSeven or FVII in patients with haemophilia A or B. Development of inhibitory antibodies to NovoSeven has been reported in a post-marketing observational registry of patients with congenital FVII deficiency. 
Izkušnje po prihodu zdravila na trg kažejo, da pri bolnikih s hemofilijo A ali B ni poročil o zaviralnih protitelesih proti zdravilu NovoSeven ali FVII.
• Take out the number of NovoSeven packages you need. 
• Vzemite toliko pakiranj zdravila NovoSeven,
• Stop pushing the plunger rod and let it move back on its own while the reconstituted solution fills the syringe. 
• Nehajte potiskati nosilec bata in pustite, da se sam od sebe pomika nazaj, medtem ko pripravljena raztopina polni injekcijsko brizgo.
The NovoSeven reconstituted solution is colourless and should be inspected visually for particulate matter and discolouration prior to administration. 
Pripravljena raztopina zdravila NovoSeven je brezbarvna in jo je treba pred uporabo pregledati, da ne vsebuje delcev in da ni obarvana.
• Store powder and solvent below 25°C. 
• Prašek in topilo shranjujte pri temperaturi do 25 °C.
• The NovoSeven powder vial and pre-filled syringe with solvent should be at room temperature at reconstitution. 
• Viala s praškom NovoSeven in napolnjena injekcijska brizga s topilom morata imeti ob pripravi sobno temperaturo.
If the protective paper is not fully sealed or it is broken do not use the vial adapter. 
Če zaščitni papir ni povsem prilepljen ali je pretrgan, nastavka za vialo ne uporabite.
If you have Factor VII deficiency: The usual dose range is 15 to 30 micrograms for every 1 kilogram you weigh, for each injection. 
Običajni odmerek za vsako injekcijo je 15 do 30 mikrogramov na vsak kilogram telesne mase.
Do not store the solution without advice from your doctor or nurse. 
Raztopine ne shranjujte brez posveta z zdravnikom ali medicinsko sestro.
Powder in vial and solvent in pre-filled syringe: 
Prašek v viali in topilo v napolnjeni injekcijski brizgi
Hold the syringe with the vial upside down and pull the plunger to draw all the solution into the syringe. 
Držite brizgo in vialo skupaj obrnjeni na glavo in potegnite bat, tako da boste potegnili vso raztopino v brizgo.
Pull the plunger to draw in a volume of air that is equal to the amount of solvent in the solvent vial (ml equals cc on the syringe). 
Potegnite bat nazaj, tako da potegnete v brizgo natanko toliko zraka, kolikor je topila v viali s topilom (mililitri ustrezajo oznaki cc na brizgi).
- Intracardiac thrombus including portal vein thrombosis, renal vein thrombosis, thrombophlebitis, superficial thrombophlebitis and intestinal ischaemia) 
tromboza ledvične vene, tromboflebitis, površinski tromboflebitis in ishemija črevesa)
No studies on the effect on the ability to drive and use machines have been performed. 
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Študij o vplivu na sposobnost vožnje in upravljanja s stroji niso izvedli.
• Keep the plunger rod pressed down and swirl the vial gently until all the powder is dissolved. 
• Nosilec bata držite pritisnjen do konca in previdno vrtite vialo, dokler se ves prašek ne raztopi.
Severity of bleeding condition and clinical response to NovoSeven administration must guide dosing requirements. 
Odmerjanje je potrebno uravnavati glede na resnosti krvavitve in kliničnem odzivu na zdravilo NovoSeven.
An initial dose of 90 µg per kg body weight should be given immediately before the intervention. 
Tik pred posegom je treba dati začetni odmerek 90 µg na kg telesne mase.
Thrombosis has been reported in FVII deficient patients receiving NovoSeven during surgery but the risk of thrombosis in factor VII deficient patients treated with NovoSeven is unknown (see section 5.1). 
Tveganje za trombozo pri bolnikih s pomanjkanjem FVII, zdravljenih z zdravilom NovoSeven, ni znano (glejte poglavje 5.1).
Once attached, do not remove the vial adapter from the vial. 
Ko je nastavek nameščen, ga ne odstranjujte več z viale.
The only complication reported in connection with an overdose was a slight transient increase in blood pressure in a 16 year-old patient receiving 24 mg rFVIIa instead of 5.5 mg. 
letnem bolniku, ki je dobil 24 mg rFVIIa namesto 5,5 mg.
Push the plunger rod to inject all the solvent into the vial. 
Potiskajte nosilec bata, da boste v vialo vbrizgali vse topilo.
Pull the plunger rod slightly downwards to draw the mixed solution into the syringe. 
Potegnite nosilec bata rahlo navzdol, da boste zmešano raztopino potegnili v brizgo.
• The syringe with adequately reconstituted product is now ready for administration in a CEmarked infusion pump (accepting a 50 ml syringe). 
• Brizga z ustrezno pripravljenim zdravilom je zdaj pripravljena za dajanje z infuzijsko črpalko
The reconstituted solution is colourless. 
Pripravljena raztopina je brezbarvna.
NovoSeven 1 mg (50 KIU) 
NovoSeven 1 mg (50 k.i.e.)
Turn the syringe with the vial upside down and withdraw the contents of the vial into the syringe. 
Obrnite brizgo z vialo na glavo in potegnite vsebino viale v brizgo.
Do not take the vial adapter out of the protective cap. 
Ne vzemite nastavka viale iz zaščitnega pokrovčka.
• Attach the syringe with the vial adapter or transfer needle to the powder vial. 
• Namestite brizgo z nastavkom za vialo ali iglo na vialo s praškom.
The closed vial is equipped with a polypropylene tamper-evident snap-off cap. 
Zaprta viala je opremljena s polipropilenskim zaščitnim snemnim pokrovčkom.
NovoSeven powder and solvent vials should be at room temperature at reconstitution. 
NovoSeven prašek in topilo morata biti za pripravo ogreta na sobno temperaturo.
The syringe cap consists of bromobutyl rubber and polypropylene tamper evident seal. 
Pokrovček brizge je iz bromobutilne gume in polipropilenskega zaščitnega pečata.
Attach the syringe with vial adapter or transfer needle to the powder vial. 
Namestite brizgo z nastavkom za vialo ali iglo na vialo s praškom.
The efficacy rates were 81% and 82%, respectively, in patients with positive or negative refractoriness to platelet transfusions, and 77% and 85%, respectively, in patients testing positive or negative for antibodies to platelets. 
Pri bolnikih s pozitivnim testom na protitelesa proti trombocitom je delež učinkovitosti znašal 77 %, pri bolnikih z negativnim testom na protitelesa proti trombocitom pa je delež učinkovitosti znašal 85 %.
If using a transfer needle, remove the protective cap and insert the transfer needle into the rubber stopper of the solvent vial. 
Če uporabljate iglo, odstranite zaščitni pokrovček in iglo zabodite v gumijasti zamašek viale s topilom.
• Push the plunger rod slowly until all air bubbles are gone. 
• Nosilec bata potiskajte, dokler vsi zračni mehurčki ne izginejo.
After reconstitution, 1 ml of the solution contains 1 mg eptacog alfa (activated). 
Po pripravi vsebuje 1 ml raztopine 1 mg aktiviranega eptakoga alfa.
Do not store the reconstituted solution without advice from your doctor or nurse. 
Pripravljene raztopine ne shranjujte brez posveta s svojim zdravnikom ali medicinsko sestro.
- Headache 
- glavobol
Turn over the protective cap, and snap the vial adapter onto the vial. 
Obrnite zaščitni pokrovček in namestite nastavek za vialo na vialo.
• Turn over the protective cap, and snap the vial adapter onto the vial. 
• Obrnite zaščitni pokrovček in namestite nastavek za vialo na vialo.
Store below 25°C Do not freeze 
Shranjujte pri temperaturi do 25 °C.
Push the plunger slowly to inject the solvent into the powder vial. 
Počasi potiskajte bat in tako vbrizgajte topilo v vialo s praškom.
NovoSeven 5 mg (250 KIU) 
NovoSeven 5 mg (250 k.i.e.)
Reconstitute the powder with the solvent • Hold the pre-filled syringe slightly tilted with the vial pointing downwards. 
Prašek zmešajte s topilom • Napolnjeno injekcijsko brizgo držite rahlo nagnjeno, tako da je viala obrnjena navzdol.
Once attached, remove the protective cap. Take care not to touch the spike on the vial adapter. 
Ko odstranjujete zaščitni pokrovček, pazite, da ne dvignete nastavka za vialo z viale.
Do not open the equipment until you are ready to use it. Do not use the equipment if it has been dropped, or if it is damaged. 
Ne uporabljajte opreme, če vam je padla ali če je poškodovana.
- 1 vial (2 ml) with white powder for solution for injection - 1 pre-filled syringe (3 ml) with solvent for reconstitution - 1 plunger rod - 1 vial adapter, with an integrated particle filter with a pore size of 25 micrometer. 
- 1 napolnjeno injekcijsko brizgo (3 ml) s topilom za pripravo raztopine, - 1 nosilec bata, - 1 nastavek za vialo z integriranim filtrom za delce z velikostjo por 25 mikrometrov.
• Keep the plunger rod pushed completely in. 
• Držite nosilec bata pritisnjen do konca.
These reactions are reported as uncommon 
Pogostnost ni znana
Lightly squeeze the protective cap with the thumb and index finger. 
S palcem in kazalcem rahlo stisnite zaščitni pokrovček.
In syringe (50 ml polypropylene) in hospital settings only Reconstitution must take place in controlled and validated aseptic conditions by adequately trained staff. 
Rekonstitucijo mora opraviti ustrezno usposobljeno osebje v nadzorovanih in preverjenih aseptičnih pogojih.
(may affect up to 1 in 100 treatment episodes) 
Občasni (pojavijo se lahko pri največ 1 od 100 epizod zdravljenja)
• The other ingredients in the powder are sodium chloride, calcium chloride dihydrate, glycylglycine, polysorbate 80, mannitol, sucrose, methionine, hydrochloric acid, sodium hydroxide. 
• Pomožne snovi v prašku so natrijev klorid, kalcijev klorid dihidrat, glicilglicin, polisorbat 80,
NovoSeven 2 mg (100 KIU) 
NovoSeven 2 mg (100 k.i.e)
Dosing frequency should initially be every second hour until clinical improvement is observed. 
Zdravilo je treba uvodoma, do kliničnega izboljšanja, dajati na dve uri.
No cases of overdose have been reported in patients with acquired haemophilia or Glanzmann's thrombasthenia. 
Med bolniki s pridobljeno hemofilijo ali Glanzmannovo trombastenijo ni opisanih primerov prevelikega odmerjanja.
Do not store reconstituted NovoSeven in plastic syringes, unless as described in section 6.3. 
Pripravljene raztopine zdravila NovoSeven ne shranjujte v plastičnih brizgah, razen v primeru,
Uncommon (may affect up to 1 in 100 treatment episodes) 
Ostali občasni neželeni učinki (pojavijo se lahko pri največ 1 od 100 epizod zdravljenja)
The powder vial contains white powder and the solvent vial contains a clear colourless solution. 
Viala s praškom vsebuje bel prašek, viala s topilom pa bistro in brezbarvno raztopino.
NovoSeven 8 mg (400 KIU) 
NovoSeven 8 mg (400 k.i.e)
During in vitro studies, the chemical and physical in-use stability has been demonstrated for 24 hours at 25°C in a 50 ml syringe (polypropylene). 
Postopek za združevanje vsebine vial (le za bolnišnično uporabo) Med študijami in vitro sta bili kemična in fizikalna stabilnost med uporabo dokazani za 24 ur pri temperaturi 25 °C v 50-mililitrski brizgi (polipropilen).
• Push the plunger rod to inject all the solvent into the vial. 
• Potiskajte nosilec bata, da boste v vialo vbrizgali celotno količino topila.
Powder in vial and solvent in vial: 
Prašek in topilo v viali
Rare (may affect up to 1 in 1,000 treatment episodes) 
Ostali redki neželeni učinki (pojavijo se lahko pri največ 1 od 1.000 epizod zdravljenja)
If the plastic cap is loose or missing, do not use the vial. 
Če plastični pokrovček ni trdno pričvrščen ali ga sploh ni, viale ne uporabite.
If you use a transfer needle, make sure to penetrate the centre of the rubber stopper. 
Če uporabljate iglo, pazite, da jo boste zabodli skozi sredino gumijastega zamaška.
• NovoSeven powder and solvent vials should be at room temperature at reconstitution. 
• Viali s praškom in topilom morata biti za pripravo ogreti na sobno temperaturo.
• Remove the empty solvent vial. 
• Odstranite prazno vialo s topilom.
If you use a transfer needle, remove the transfer needle from the vial, replace the transfer needle cap, and twist the transfer needle off the syringe. 
Če uporabljate iglo, izvlecite iglo iz viale, pokrijte jo s pokrovčkom igle in iglo odvijte z brizge.
After reconstitution, the product contains 1 mg/ml eptacog alfa (activated) when reconstituted with solvent. 
Po rekonstituciji s topilom vsebuje zdravilo 1 mg/ml aktiviranega eptakoga alfa.
Screw the syringe tightly onto the vial adapter on the solvent vial. 
Brizgo trdno privijte v nastavek za vialo na viali s topilom.
If the syringe cap is loose or missing, do not use the pre-filled syringe. 
Če pokrovček brizge ne sedi trdno ali ga sploh ni, napolnjene injekcijske brizge ne uporabite.
• Screw the plunger rod clockwise into the plunger inside the pre-filled syringe until resistance is felt. 
• Privijte nosilec bata v smeri urinega kazalca v bat, ki je v notranjosti napolnjene injekcijske brizge, dokler ne začutite upora.
Screw the syringe securely onto the vial adapter until resistance is felt. 
Injekcijsko brizgo trdno privijte na nastavek za vialo, dokler ne začutite upora.
Dose, dose range and dose interval 
Odmerek, odmerno območje in odmerni interval
Eptacog alfa (activated) 8 mg/vial (400 KIU/vial), 1 mg/ml after reconstitution 
Aktivirani eptakog alfa, 8 mg/vialo (400 k.i.e./vialo), 1 mg/ml po pripravi;
- Related laboratory findings, including elevated levels of Ddimmer and decreased levels of AT (see section 
- povezani laboratorijski izvidi, vključno s povečano koncentracijo
• If using a vial adapter, unscrew the vial adapter with the empty vial. 
• Če uporabljate nastavek za vialo, odvijte nastavek za vialo in prazno vialo.
Powder and solvent for solution for injection Eptacog alfa (activated) 
prašek in topilo za raztopino za injiciranje aktivirani eptakog alfa
• 1 pre-filled syringe with solvent for reconstitution 
• 1 napolnjeno injekcijsko brizgo s topilom za pripravo raztopine,
If you touch the syringe tip, germs from your fingers can be transferred. 
Če se dotaknete konice injekcijske brizge, lahko nanjo prenesete klice s prstov.
Clean the rubber stoppers on the vials with alcohol swabs and allow them to dry before use. 
Gumijasta zamaška na vialah očistite z alkoholnima zložencema.
Thread 
Odmerek
Eptacog alfa (activated) 5 mg/vial (250 KIU/vial), 1 mg/ml after reconstitution 
Aktivirani eptakog alfa, 5 mg/vialo (250 k.i.e./vialo), 1 mg/ml po pripravi;
NovoSeven is presented as powder and solvent for solution for injection containing 5 mg eptacog alfa (activated) per vial (corresponds to 250 KIU/vial). 
Zdravilo NovoSeven je na voljo kot prašek in topilo za raztopino za injiciranje in vsebuje 5 mg aktiviranega eptakoga alfa na vialo (ustreza 250 k.i.e./vialo).
Acquired Haemophilia 
Pridobljena hemofilija
Immediately connect the plunger rod to the syringe by turning it clockwise into the plunger inside the pre-filled syringe until resistance is felt. 
• Takoj privijte nosilec bata v injekcijsko brizgo, tako da ga vrtite v smeri urinega kazalca v bat, ki je v notranjosti napolnjene injekcijske brizge,
White lyophilised powder. 
prašek in topilo za raztopino za injiciranje Bel liofiliziran prašek.
NovoSeven is presented as powder and solvent for solution for injection containing 8 mg eptacog alfa (activated) per vial (corresponds to 400 KIU/vial). 
Zdravilo NovoSeven je na voljo kot prašek in topilo za raztopino za injiciranje in vsebuje 8 mg aktiviranega eptakoga alfa na vialo (ustreza 400 k.i.e./vialo).
Eptacog alfa (activated) 2 mg/vial (100 KIU/vial), 1 mg/ml after reconstitution 
Aktivirani eptakog alfa, 2 mg/vialo (100 k.i.e./vialo), 1 mg/ml po pripravi;
Gently swirl the vial until all the powder is dissolved. 
Previdno vrtite vialo, dokler se prašek ne raztopi.
Powder vial 
gumijasti zamašek
• Screw the syringe tightly onto the vial adapter on the solvent vial. 
• Brizgo trdno privijte v nastavek za vialo na viali s topilom.
Administration 
Aplikacija
If you use a transfer needle, make sure that the transfer needle tip is in the solution. 
Če uporabljate iglo, poskrbite, da bo konica igle v topilu.
NovoSeven is presented as powder and solvent for solution for injection containing 1 mg eptacog alfa (activated) per vial (corresponds to 50 KIU/vial). 
Zdravilo NovoSeven je na voljo kot prašek in topilo za raztopino za injiciranje in vsebuje 1 mg aktiviranega eptakoga alfa na vialo (ustreza 50 k.i.e./vialo).
In clinical trials of patients with factor VII deficiency, formation of antibodies against NovoSeven and FVII is the only adverse drug reaction reported (frequency: common (≥ 1/100 to < 1/10)). 
Pojav protiteles proti zdravilu NovoSeven in FVII je edini neželeni učinek zdravila, opisan v kliničnih preskušanjih bolnikov s pomanjkanjem faktorja VII, izpostavljenih zdravilu NovoSeven (pogostnost:
NOVOSEVEN USER INSTRUCTIONS 
NAVODILA ZA UPORABO
If the caps are loose or missing, do not use the vials. 
Če pokrovček ne sedi trdno ali ga sploh ni, viale ne uporabite.
- For storage conditions of the reconstituted medicinal product, see section 6.3. 
- Za pogoje shranjevanja pripravljenega zdravila glejte poglavje 6.3. 6.5 Vrsta ovojnine in vsebina
Hold the syringe slightly tilted with the vial pointing downwards. 
Držite brizgo rahlo nagnjeno, tako da je vstavljena viala spodaj.
Eptacog alfa (activated) 1 mg/vial (50 KIU/vial), 1 mg/ml after reconstitution 
Aktivirani eptakog alfa, 1 mg/vialo (50 k.i.e./vialo), 1 mg/ml po pripravi;
If you use a vial adapter, unscrew the vial adapter with the empty vial. 
Če uporabljate nastavek za vialo, odvijte nastavek za vialo in prazno vialo.
1 vial of powder 
Nalepka za vialo s praškom
NovoSeven is presented as powder and solvent for solution for injection containing 2 mg eptacog alfa (activated) per vial (corresponds to 100 KIU/vial). 
Zdravilo NovoSeven je na voljo kot prašek in topilo za raztopino za injiciranje in vsebuje 2 mg aktiviranega eptakoga alfa na vialo (ustreza 100 k.i.e./vialo).
You should talk to your doctor before using NovoSeven with these medicines. 
Preden uporabite zdravilo NovoSeven skupaj s temi zdravili, se morate posvetovati s svojim zdravnikom.
• 1 pre-filled syringe with solvent 
• 1 napolnjeno injekcijsko brizgo s topilom,
Rare (≥1/10,000 to <1/1,000) Frequency Not Known 
pogosto (≥ 1/100 do < 1/10)).
• Turn the syringe with the vial upside down. 
• Obrnite brizgo skupaj z vialo s topilom na glavo.
• Gently swirl the vial until all the powder is dissolved. 
• Previdno vrtite vialo, dokler se prašek ne raztopi.
The NovoSeven 1 mg (50 KIU)/NovoSeven 2 mg (100 KIU) package contains either - 1 vial (2 ml) with white powder for solution for injection - 1 vial (2 ml) with solvent for reconstitution or 
vsebuje: - 1 vialo (2 ml) z belim praškom za raztopino za injiciranje, - 1 vialo (2 ml) s topilom za pripravo raztopine ali
NovoSeven is now ready to inject into your vein. 
Zdravilo NovoSeven je zdaj pripravljeno za injiciranje v veno.
If you touch the spike on the vial adapter germs from your fingers can be transferred. 
Če se dotaknete konice nastavka za vialo, lahko nanj prenesete klice s prstov.
1 pre-filled syringe of solvent with separate plunger rod 1 vial adapter for reconstitution 
1 napolnjeno injekcijsko brizgo s topilom in ločen nosilec bata,
How to store NovoSeven 
Shranjevanje zdravila NovoSeven
- Nausea 
Žilne bolezni
Hydrochloric acid (for pH-adjustment) Sodium hydroxide (for pH-adjustment) 
Prašek natrijev klorid kalcijev klorid dihidrat glicilglicin polisorbat 80 manitol saharoza metionin klorovodikova kislina (za uravnavanje pH) natrijev hidroksid (za uravnavanje pH)
NovoSeven 1 mg (50 KIU) powder and solvent for solution for injection NovoSeven 2 mg (100 KIU) powder and solvent for solution for injection NovoSeven 5 mg (250 KIU) powder and solvent for solution for injection NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection 
prašek in topilo za raztopino za injiciranje NovoSeven 5 mg (250 k.i.e.)
NovoSeven 8 mg Powder for injection Eptacog alfa (activated) IV 
NovoSeven 8 mg prašek za injekcijo aktivirani eptakog alfa i.v.
Other uncommon side effects 
Preglednica neželenih učinkov
Administer the solution as an intravenous bolus injection over 2 - 5 minutes. 
Aplicira se ga v intravenski bolusni injekciji.
Do not reuse the equipment. 
Opremo uporabite samo enkrat.
90 µg/kg (range 28 to 450 µg/kg). 
Mediani odmerek na aplikacijo pri zdravljenju 333 epizod krvavitev je znašal 90 µg/kg (razpon od 28 do 450 µg/kg).
NovoSeven 1 mg Powder for injection Eptacog alfa (activated) IV 
NovoSeven 1 mg prašek za injekcijo aktivirani eptakog alfa i.v.
NovoSeven 5 mg Powder for injection Eptacog alfa (activated) IV 
NovoSeven 5 mg prašek za injekcijo aktivirani eptakog alfa i.v.
Hold the syringe slightly tilted with the vial facing downwards. 
Držite injekcijsko brizgo rahlo nagnjeno in tako, da je viala obrnjena navzdol.
NovoSeven 2 mg Powder for injection Eptacog alfa (activated) IV 
NovoSeven 2 mg prašek in topilo za raztopino za injiciranje aktivirani eptakog alfa
Vial adapter Protective cap 
Namestite nastavek za vialo
Syringe cap 
- tromb v srcu
Do not store the solution without your doctor's advice. 
Raztopine za injiciranje ne shranjujte, ne da bi se prej posvetovali z zdravnikom.